Oct 29, 6:47 AM ET
Tenet Healthcare reported third quarter 2026 net income available to common shareholders of $1.000 billion, or $12.41 per diluted share, up from $342 million, or $3.86, a year earlier, and raised its full-year 2026 Adjusted EBITDA outlook to $5.05 billion to $5.20 billion. The quarter includes a $147 million favorable net impact from timing-related adjustments tied to the early conclusion of revenue cycle management agreements with CommonSpirit Health, which the company says do not change its full-year revenue expectations.
- Third quarter 2026 net income available to common shareholders was $1.000 billion, or $12.41 per diluted share, versus $342 million, or $3.86, in third quarter 2025.
- Consolidated Adjusted EBITDA rose 23.3% to $1.355 billion, and adjusted diluted EPS increased 79.5% to $6.64.
- FY 2026 Adjusted EBITDA outlook is now $5.05 billion to $5.20 billion, a $195 million increase at the midpoint of the range.
- Third quarter results include a $147 million favorable net impact from transition activities and timing-related adjustments under the CommonSpirit agreements.
Read the filing on SEC.gov ↗
Sep 22, 4:06 PM ET
Tenet Healthcare issued $2 billion of 6.250% senior notes due 2034 on September 22, 2026. The company plans to use the net proceeds, with cash on hand, to redeem its $1.5 billion of 5.125% secured notes due 2027 and partly redeem $0.5 billion of its 6.125% notes due 2028. The deal refinances existing debt, and the filing does not state a change in total debt outstanding.
- Issued $2,000,000,000 of 6.250% senior notes due 2034 on September 22, 2026
- Proceeds, with cash on hand, to fund redemption of all $1.5 billion of 5.125% senior secured first lien notes due November 2027
- Partial redemption of $0.5 billion of 6.125% senior notes due October 2028
- Notes are redeemable at a make-whole premium before September 15, 2029, and at set redemption prices after that date
Read the filing on SEC.gov ↗
Jul 23, 4:07 PM ET
Tenet Healthcare reported second-quarter 2026 results on July 23, 2026, with net operating revenues of $5.628 billion, up 6.8% from a year earlier, and net income to common shareholders of $826 million, or $9.84 per diluted share, versus $288 million, or $3.14, in the second quarter of 2025. The company raised its full-year 2026 adjusted EBITDA outlook and authorized a $2.0 billion increase to its share repurchase program, which matters to shareholders because it lifts expected earnings and returns capital.
- Adjusted diluted EPS rose 52.2% to $6.12 from $4.02 a year earlier.
- Net income includes $413 million of revenue from the early termination of the CommonSpirit contract, which is excluded from net operating revenues.
- FY 2026 adjusted EBITDA outlook is now $4.83 billion to $5.03 billion, a $295 million increase at the midpoint; adjusted free cash flow outlook is $2.725 billion to $3.025 billion.
- The Board authorized a $2.0 billion increase to the share repurchase program, leaving $2.13 billion available as of July 23, 2026.
Read the filing on SEC.gov ↗
Apr 30, 6:47 AM ET
Tenet Healthcare reported first quarter 2026 net income available to common shareholders of $702 million, or $8.01 per diluted share, up from $406 million, or $4.27, a year earlier. Results include $413 million of revenue from the early conclusion of a contract with CommonSpirit Health, while adjusted EBITDA was roughly flat at $1.162 billion, and the company kept its full-year 2026 adjusted EBITDA outlook of $4.485 billion to $4.785 billion unchanged.
- Net operating revenues rose 2.8% to $5,368 million from $5,223 million a year earlier.
- Adjusted diluted EPS rose 10.6% to $4.82 from $4.36; GAAP diluted EPS was $8.01 versus $4.27.
- Adjusted EBITDA was $1.162 billion versus $1.163 billion, and the full-year 2026 adjusted EBITDA outlook was kept at $4.485 billion to $4.785 billion.
- The company repurchased 1.35 million shares for $318 million in the quarter.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
